ONLINE MUTATION REPORT

A novel *GATA4* mutation completely segregated with atrial septal defect in a large Japanese family

A Okubo, O Miyoshi, K Baba, M Takagi, K Tsukamoto, A Kinoshita, K Yoshiura, T Kishino, T Ohta, N Niikawa, N Matsumoto

J Med Genet 2004;41:e97 (<http://www.jmedgenet.com/cgi/content/full/41/7/e97>). doi: 10.1136/jmg.2004.018895

Atrial septal defect (ASD) is characterised by left-to-right shunting and increased right ventricular output.¹ Approximately 5–10% of congenital heart diseases (CHD) are due to ASD which is one of the most frequent CHD found in human adults.² ASD has been presumed to be caused by genetic factors.^{3–4} Recently, a few genes have been implicated in syndromic and non-syndromic ASD. Mutations in *T-BOX5* at 12q24.1,⁵ *NKX2.5* at 5q34,⁷ *EVC* at 4p16.1,⁹ and *GATA4* at 8p23.1–p22¹⁰ cause Holt-Oram syndrome with ASD or ventricular septal defect (VSD), non-syndromic CHD including ASD and atrioventricular conduction abnormalities, Ellis-van Creveld syndrome with ASD, and a familial isolated ASD, respectively.

We encountered a large family of four generations where 11 members were affected with ASD, and where disease transmission was consistent with an autosomal dominant mode of inheritance. Here we report a novel mutation of *GATA4* in this family.

METHODS

Subjects

A large Japanese family composed of a total of 29 members across four generations contained 11 members with ASD (I-1, II-2, II-6, II-7, III-1, III-2, III-4, IV-1, IV-2, IV-5, and IV-6; fig 1A). ASD in five patients (II-7, III-1, III-2, IV-1, and IV-2) was surgically repaired, and two patients (II-2 and IV-1) also had pulmonary stenosis (PS). The heart defects in eight subjects (II-2, II-7, III-1, III-2, IV-1, and IV-2) including two diseased subjects (I-1 and II-6) had been clinically diagnosed by one of co-authors (BK) on the basis of their past histories, operation records, 12-lead electrocardiograms, and echocardiograms with colour Doppler apparatus (fig 1A), while those in three other subjects (III-4, IV-5, and IV-6) were retrospectively found using information provided by the mutation analysis described below. None of the 11 affected members had any other abnormalities in the cardiac conduction system or other organs. After informed consent was obtained, DNA was extracted from peripheral blood leukocytes of 22 family members.

Linkage and mutation analyses

Linkage analysis was performed in 22 family members at 11 microsatellite marker loci around *GATA4* at 8p23 (D8S561, D8S503, D8S1721, D8S550, D8S265, D8S552, D8S1790, D8S549, D8S254, D8S258, and D8S1771), and two-point linkage analysis was carried out using the computer program MLINK (FASTLINK software, version 4.1P), as described previously.¹¹ III-4, IV-5, and IV-6 were regarded as unaffected at this initial linkage analysis.

All exons in the 22 members covering the coding region of *GATA4* were then amplified by PCR. PCR and sequencing primers are shown in table 1. PCR was cycled 35 times at 98°C for 30 s, 55–58°C for 30 s, 72°C for 1 min in a 25 µl mixture containing 1×ThermalAce Buffer (or 1×Ex Taq

Key points

- Linkage analysis in a large Japanese family with atrial septal defect (ASD) suggested *GATA4* as a possible candidate gene for heart disease.
- Mutation analysis of *GATA4* identified a novel 1 bp deletion (c.1074delC) at exon 6 in all nine family members with ASD, but not in the family members without the disease.
- This is the second report linking *GATA4* mutation with an isolated congenital heart defect.

Buffer (Takara, Ohtsu, Japan)), 0.2 mM each dNTP, 0.5 µM each primer, and 1 U ThermalAce DNA polymerase (Invitrogen, Carlsbad, USA) (or 0.5 U TaKaRa Ex Taq™ DNA polymerase (TaKaRa)). PCR products were purified using ExoSap-IT (USB, OH, USA) and sequenced by a standard protocol using BigDye Terminator (Applied Biosystems, Foster City, CA, USA) on an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems). *GATA4* sequences of affected members were compared with those of normal controls using Autoassembler 2.1 (Applied Biosystems).

RESULTS AND DISCUSSION

Linkage analysis gave a maximum LOD score of 1.61 (recombination fraction (θ) = 0, penetrance = 0.65) at D8S552 on 8p23.1–p22, the findings suggesting *GATA4* as a possible candidate gene for ASD in this family. The sequence analysis revealed that nine (II-2, II-7, III-1, III-2, III-4, IV-1, IV-2, IV-5, and IV-6) of the 22 members had a heterozygous 1 bp deletion (c.1074delC) at exon 6 of *GATA4* (fig 1B). The 1 bp deletion results in a frame shift and is predicted to create a premature stop codon at amino acid 403, leading to protein truncation (fig 1C). The mutation was never observed in 13 unaffected members of the family or in 100 normal controls.

Early and precise diagnosis of ASD is clinically important, because leaving it uncorrected until adulthood may result in right heart failure, although some patients with minor ASD can often lead a healthy life. As the mortality rate of ASD operations is very low in patients without cardiac failure under the age of 45,¹ early surgical intervention is feasible. Clinical re-evaluation of three members (III-4, IV-5, and IV-6) who were previously thought to be unaffected confirmed their disease. Thus, penetrance in the pedigree we describe is actually complete. This information will be very

Abbreviations: ASD, atrial septal defect; CHD, congenital heart diseases; PS, pulmonary stenosis; TOF, tetralogy of Fallot; VSD, ventricular septal defect

Figure 1 (A) Pedigree of a large Japanese family with heart defects, haplotypes at marker loci on chromosome 8, and *GATA4* mutation. ASD was observed in 11 members and PS in two. A common haplotype associated with ASD at eight marker loci, D8S503, D8S1721, D8S550, D8S265, D8S552, D8S1790, D8S549, and D8S254, was boxed. All members with the heart defects had a *GATA4* mutation, c.1074delC. (B) Electropherogram of an unaffected family member with wild type alleles of *GATA4* (upper), and an affected member heterozygous for a mutated allele, c.1074del, at exon 6 of *GATA4* (lower). (C) Wild type (WT) and mutated (MU) amino acid sequences of *GATA4* protein. The c.1074del causes a frame shift and creates a premature stop codon at amino acid 403.

useful for genetic counselling for this family, because testing for c.1074delC in new family members can be followed by careful medical examination and prophylactic intervention if ASD is found. Revised linkage analysis using information from newly confirmed patients (III-4, IV-5, and IV-6) provided a maximum LOD score of 4.43 (recombination fraction (θ) = 0, penetrance = 0.95) at D8S552.

ASD in two patients with the mutation in our family was associated with PS. A similar finding has been reported in

two families with *GATA4* mutations by Garg *et al*¹⁰: one family (family B) had isolated ASD and a deletion mutation, c.1075delG, while the other (family A) presented with complex heart defects such as atrioventricular septal defect, PS, aortic regurgitation, patent ductus arteriosus in addition to ASD, and a missense mutation, c.886 G>A (G296S). The missense mutation, c.886 G>A, disturbed the interaction between *GATA4* and *TBX5*.¹⁰ *TBX5* and *NKX2-5* mutations can cause Holt-Oram syndrome with tetralogy of Fallot (TOF)

Table 1 PCR primer sequences

Exon	Forward (5'–3')	Reverse (5'–3')	Product size (bp)
1	AGACCCAGAGCCTGGACTT	GCAAAGTCAAAAGCAGAGCA	448
2–1	AACGCCTGGACAAAACAAAG	CCAAGCTCTGATACATGGTC	652
2–2	CAGTTCCTCCACGCATATT	CTTCTGCTTCCCTAGAAAC	872
3	AAAGGGCATTGTTTCTGTGC	GATGCACACCTCAAGTTC	377
4	GGGCAGTGCACACCTTTTAC	GAGAGATGGGCATCAGAAGG	232
5	GCTTAGGTGTGCTTCTCG	TGCCTAACCCGGAAGATATG	270
6	ACTGTAGCCCTCCGCAGATA	TGAGGCCTGGTGCAAGTC	404
7–1	ACATCTGCATAGCAGGGCAC	TGCCATGCCTCAAGCGGAT	755
7–2	CGAGGATCTGAGAACCAAGCG	CGTGTGCAGAAATCTCTGGC	755
7–3	GCTCAAGCCAGTCTGGCAAG	AGTGGGTCAGTGCTACACG	755

Sequencing primers are the same as PCR primers except for 2–1 forward, 2–1 reverse, 2–2 reverse, and 7–3 reverse. Sequences (5'–3') of newly designed sequencing primers for 2–1 forward, 2–1 reverse, 2–2 reverse, and 7–3 reverse are AGCGTGAAGAAGCAACCAC, GTCTTGTGCCCCCAATAGGT, GAAGGCGTGGTGAAAAAC, and TTCTCTCTGCACATGCTG, respectively.

and non-syndromic TOF, respectively.^{5 12 13}. TOF includes PS. As GATA4 functionally interacts with TBX5 and NKX2-5,^{10 14 15} the c.1074delC in the family we described may disturb the coordinated interaction between GATA4 and TBX5 or NKX2-5 in cardiogenesis, resulting in PS in the two affected members of our family. It is also noted that the truncated protein generated by the c.1074delC is very similar to that generated by the c.1075delG except for a serine residue. It is likely that the c.1074delC is unable to activate transcription of downstream genes, being similar to the c.1075delG as reported by Garg *et al.*¹⁰ In summary, the GATA4 c.1074delC likely results in haploinsufficiency, and causes a cardiac phenotype similar to that described in 8p deletion syndrome.¹⁶ In addition, a syndromic PS associated with Noonan/LEOPARD syndrome and Alagille syndrome has been shown to be caused by mutations of *PTPN11* at 12q22^{17 18} and *JAG1* at 20p12,^{19 20} respectively. *JAG1* mutation can also result in isolated PS.²¹ It might be interesting to investigate the relationship between GATA4 and *PTPN11* or *JAG1*.

In conclusion, we identified a 1 bp deletion of *GATA4* in a large Japanese family with ASD. Segregation of ASD with the *GATA4* mutation with complete penetrance in this family suggests that one type of ASD is caused by a single gene defect. It remains to be seen how much *GATA4* mutations contribute to the pathogenesis of congenital heart defects in man.

Authors' affiliations

A Okubo, O Miyoshi, A Kinoshita, K Yoshiura, N Niikawa, N Matsumoto, Department of Human Genetics, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
A Okubo, K Tsukamoto, Department of Clinical Pharmacy, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
O Miyoshi, Department of Psychiatry, Mie University School of Medicine, Tsu, Japan
K Baba, Baba Clinic, Nagasaki, Japan
M Takagi, Joseph Clinic, Nagasaki, Japan
A Kinoshita, K Yoshiura, T Kishino, T Ohta, N Niikawa, N Matsumoto, CREST, Japan Science and Technology Agency, Kawaguchi, Japan
T Kishino, T Ohta, Division of Functional Genomics, Center for Frontier Life Sciences, Nagasaki University, Nagasaki, Japan
N Matsumoto, Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan

Conflict of interest: none declared.

Correspondence to: Dr N Matsumoto, Department of Human Genetics, Yokohama City University Graduate School of Medicine, Fukuura 3–9, Kanazawa-ku, Yokohama 236–0004, Japan; naomat@yokohama-cu.ac.jp

Received 28 January 2004

Accepted for publication 24 February 2004

REFERENCES

- 1 Tierney LM. *Current medical diagnosis and treatment*, 40th ed. New York: McGraw-Hill, 2001.
- 2 Hoffman JL. Congenital heart disease: incidence and inheritance. *Pediatr Clin North Am* 1990;**37**:25–43.
- 3 Ferencz C, Boughman JA, Neill CA, Brenner JJ, Perry LW. Congenital cardiovascular malformations: questions on inheritance. Baltimore-Washington Infant Study Group. *J Am Coll Cardiol* 1989;**14**:756–63.
- 4 Benson DW, Sharkey A, Fatkin D, Lang P, Basson CT, McDonough B, Strauss AW, Seidman JG, Seidman CE. Reduced penetrance, variable expressivity, and genetic heterogeneity of familial atrial septal defects. *Circulation* 1998;**97**:2043–8.
- 5 Li QY, Newbury-Ecob RA, Terrett JA, Wilson DI, Curtis AR, Yi CH, Gebuhr T, Bullen PJ, Robson SC, Strachan T, Bonnet D, Lyonnet S, Young ID, Raeburn JA, Buckler AJ, Law DJ, Brook JD. Holt-Oram syndrome is caused by mutations in *TBX5*, a member of the Brachyury (T) gene family. *Nat Genet* 1997;**15**:21–9.
- 6 Fan C, Duhagon MA, Overti C, Chen S, Hiroi Y, Komuro I, Duhagon PI, Canessa R, Wang Q. Novel *TBX5* mutations and molecular mechanism for Holt-Oram syndrome. *J Med Genet* 2003;**40**:e29.
- 7 Schott JJ, Benson DW, Basson CT, Pease W, Silberbach GM, Moak JP, Maron BJ, Seidman CE, Seidman JG. Congenital heart disease caused by mutations in the transcription factor *NKX2-5*. *Science* 1998;**281**:108–11.
- 8 Benson DW, Silberbach GM, Kavanaugh-McHugh A, Cottrill C, Zhang Y, Riggs S, Smalls O, Johnson MC, Watson MS, Seidman JG, Seidman CE, Plowden J, Kugler JD. Mutations in the cardiac transcription factor *NKX2.5* affect diverse cardiac developmental pathways. *J Clin Invest* 1999;**104**:1567–73.
- 9 Ruiz-Perez VL, Ide SE, Strom TM, Lorenz B, Wilson D, Woods K, King L, Francomano C, Freisinger P, Spranger S, Marino B, Dallapiccola B, Wright M, Meitinger T, Polymeropoulos MH, Goodship J. Mutations in a new gene in Ellis-van Creveld syndrome and Weyers acrocardial dysostosis. *Nat Genet* 2000;**24**:283–6.
- 10 Garg V, Kathiriyi IS, Barnes R, Schluterman MK, King IN, Butler CA, Rothrock CR, Eapen RS, Hirayama-Yamada K, Joo K, Matsuoka R, Cohen JC, Srivastava D. GATA4 mutations cause human congenital heart defects and reveal an interaction with *TBX5*. *Nature* 2003;**424**:443–7.
- 11 Komatsu K, Nakamura N, Ghadami M, Matsumoto N, Kishino T, Ohta T, Niikawa N, Yoshiura K. Confirmation of genetic homogeneity of nonsyndromic low-frequency sensorineural hearing loss by linkage analysis and a DFNA6/14 mutation in a Japanese family. *J Hum Genet* 2002;**47**:395–9.
- 12 McElhinney DB, Geiger E, Blinder J, Woodrow Benson D, Goldmuntz E. *NKX2.5* mutations in patients with congenital heart disease. *J Am Coll Cardiol* 2003;**42**:1650–5.
- 13 Goldmuntz E, Geiger E, Benson DW. *NKX2.5* mutations in patients with tetralogy of Fallot. *Circulation* 2001;**104**:2565–8.
- 14 Sepulveda JL, Vlahopoulos S, Iyer D, Belaguli N, Schwartz RJ. Combinatorial expression of *GATA4*, *Nkx2-5*, and serum response factor directs early cardiac gene activity. *J Biol Chem* 2002;**277**:25775–82.
- 15 Durocher D, Charron F, Warren R, Schwartz RJ, Nemer M. The cardiac transcription factors *Nkx2-5* and *GATA-4* are mutual cofactors. *EMBO J* 1997;**16**:5687–96.
- 16 Pehlivan T, Pober BR, Brueckner M, Garrett S, Slaugh R, Van Rheeden R, Wilson DB, Watson MS, Hing AV. *GATA4* haploinsufficiency in patients with interstitial deletion of chromosome region 8p23.1 and congenital heart disease. *Am J Med Genet* 1999;**83**:201–6.
- 17 Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery S, Kalidas K, Patton MA, Kucherlapati RS, Gelb BD. Mutations in *PTPN11*, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. *Nat Genet* 2001;**29**:465–8.
- 18 Sarkozy A, Conti E, Seripa D, Digilio MC, Grifone N, Tandoi C, Fazio VM, Di Ciommo V, Marino B, Pizzuti A, Dallapiccola B. Correlation between *PTPN11*

- gene mutations and congenital heart defects in Noonan and LEOPARD syndromes. *J Med Genet* 2003;**40**:704–8.
- 19 **Oda T**, Elkahoul AG, Meltzer PS, Chandrasekharappa SC. Identification and cloning of the human homolog (JAG1) of the rat Jagged1 gene from the Alagille syndrome critical region at 20p12. *Genomics* 1997;**43**:376–9.
 - 20 **Li L**, Krantz ID, Deng Y, Genin A, Banta AB, Collins CC, Qi M, Trask BJ, Kuo WL, Cochran J, Costa T, Pierpont ME, Rand EB, Piccoli DA, Hood L, Spinner NB. Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. *Nat Genet* 1997;**16**:243–51.
 - 21 **Krantz ID**, Piccoli DA, Spinner NB. Clinical and molecular genetics of Alagille syndrome. *Curr Opin Pediatr* 1999;**11**:558–64.